Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end

Century Therapeutics, Inc.

2023-Q2 EPS reported -$1.10 revenue$1,819,000

Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.
Cash, equivalents, and investments $301.0M as of June 30, 2023; runway expected into 2026.
Phase 1 ELiPSE-1 trial of CNTY-101 ongoing; initial data from Schedule A expected by year end 2023.
Full year GAAP operating expense guidance $135M-$145M; includes $12M-$17M stock-based compensation.
Recorded $4.2M impairment charge for consolidation of two leased facilities in Philadelphia.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $33.3 million for the three months ended June 30, 2023. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Net income: Net loss was $33.3 million for the three months ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.